NAD+ (injectable)
naturally occurring coenzyme (a dinucleotide, not a peptide)
Also called: LY3437943, reta, GLP-3 (slang), triple agonist
Retatrutide is an investigational once-weekly injectable from Eli Lilly that activates three hormone receptors (GIP, GLP-1 and glucagon), one more than tirzepatide. It is in phase 3 trials for obesity and related conditions and is not approved anywhere.
Its trial weight-loss numbers are the largest reported for any obesity drug so far, so it has a reputation as the next-generation cutting drug. Gray-market 'research' versions circulate well ahead of any approval.
Human evidence: moderate. Large phase 2 and phase 3 randomized trials exist for obesity and related conditions, but the drug is still investigational and long-term safety is not yet established.
Not named on the 2026 list. Sport Integrity Australia states GLP-1 agonists are not currently prohibited; some analysts argue that unapproved retatrutide could be caught by the S0 (non-approved substances) catch-all.
Unclear. Sources disagree because it is unapproved. A tested lifter should get a written answer from Global DRO or USADA first. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.
Investigational, not FDA-approved. Lilly has said it plans to submit to FDA by Q1 2027 (per July 2026 reporting). Anything sold now as 'retatrutide' or 'LY3437943' outside a clinical trial is an unapproved product; FDA warning letters to online peptide sellers in August-September 2026 treated such products as unapproved new drugs.
As of 2026-10-01.
Semaglutide. FDA-approved (Ozempic for type 2 diabetes; Wegovy for chronic weight management). FDA declared the semaglutide shortage resolved on Feb 21, 2025, ending broad shortage-based compounding. The Fifth Circuit upheld FDA's shortage removals for semaglutide and tirzepatide in 2026. A 2026 MRI sub-analysis of the STEP UP trial found semaglutide reduced fat and also skeletal muscle volume, while sit-to-stand performance was preserved.
Tirzepatide. FDA-approved (Mounjaro for type 2 diabetes; Zepbound for weight management and obstructive sleep apnea). It is a dual GIP/GLP-1 agonist and was also removed from FDA's shortage list.
WADA. Semaglutide and tirzepatide are not prohibited; markers are on the WADA Monitoring Program.
Not named on the 2026 list. Sport Integrity Australia states GLP-1 agonists are not currently prohibited; some analysts argue that unapproved retatrutide could be caught by the S0 (non-approved substances) catch-all. Unclear. Sources disagree because it is unapproved. A tested lifter should get a written answer from Global DRO or USADA first. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.
Investigational, not FDA-approved. Lilly has said it plans to submit to FDA by Q1 2027 (per July 2026 reporting). Anything sold now as 'retatrutide' or 'LY3437943' outside a clinical trial is an unapproved product; FDA warning letters to online peptide sellers in August-September 2026 treated such products as unapproved new drugs.
Moderate. Large phase 2 and phase 3 randomized trials exist for obesity and related conditions, but the drug is still investigational and long-term safety is not yet established.
Research-use-only information file. Nothing here is medical advice or instructions for use. Not evaluated by the FDA. Talk to your doctor.
naturally occurring coenzyme (a dinucleotide, not a peptide)
synthetic 15-amino-acid peptide fragment derived from a protein found in gastric juice
synthetic peptide based on thymosin beta-4, an actin-binding protein found in most cells